Improved nerve visualization to reduce unintended intraoperative nerve injury

Illuminare Biotechnologies

Illuminare Biotechnologies is a clinical stage biotechnology company focused on intra-operative nerve visualization to reduce the risk of nerve damage. Our proprietary lead candidate, Illuminare-1, is a small molecule with an immediate onset of action and sustained duration of nerve illumination. Illuminare-1 is in final stages of completing a first-in-human trial in radical prostatectomy at Memorial Sloan Kettering Cancer Center to demonstrate safety and initial efficacy improving visualization of nerves (more infomation about clinical trial). The company expects to enter Phase 2 in 2024.

Learn More